Rapid Dose Therapeutics Corp.
DOSE
CNSX
| 08/31/2025 | 05/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -11.87% | 19.16% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -11.87% | 19.16% | |||
| Cost of Revenue | -22.29% | 15.83% | |||
| Gross Profit | -1.51% | 22.68% | |||
| SG&A Expenses | 0.92% | -49.34% | |||
| Depreciation & Amortization | 3.57% | 128.30% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.16% | -34.90% | |||
| Operating Income | -10.38% | 61.81% | |||
| Income Before Tax | -16.92% | 56.20% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -16.92% | 56.20% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.92% | 56.20% | |||
| EBIT | -10.38% | 61.81% | |||
| EBITDA | -11.55% | 64.10% | |||
| EPS Basic | -87.18% | 58.06% | |||
| Normalized Basic EPS | -91.67% | 58.62% | |||
| EPS Diluted | -87.18% | 58.06% | |||
| Normalized Diluted EPS | -91.67% | 58.62% | |||
| Average Basic Shares Outstanding | -37.17% | 4.47% | |||
| Average Diluted Shares Outstanding | -37.17% | 4.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||